Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical (NASDAQ:RARE) reaffirmed revenue and 2026 combined R&D and SG&A guidance, expecting flat to down low single digits from 2025, and at least a 15% decline in 2027. In Q2, Crysvita patient starts rose in Latin America and Turkey, and DOJOLVI had about 675 reimbursed patients in North America. FDA PDUFA dates are Aug. 23 for DTX-401 and Sept. 19 for UX-111.
The FDA’s August 2026 Prescription Drug User Fee Act calendar includes target action dates for multiple investigational drugs and therapies. Moderna’s mRNA-1010 has an Aug 5, 2026 PDUFA date. Gilead’s bictegravir/lenacapavir has Aug 27. Lantheus’ MK-6240 has Aug 13. Other listed PDUFA dates cover programs from Capricor, BMS, Jazz, Savara, Ultragenyx, PharmaEssentia, Regeneron, Takeda, and Priovant.
Analysts at Bank of America and Jefferies reiterated bullish views on Ultragenyx Pharmaceutical (RARE) and Danaher (DHR). Bank of America analyst Tazeen Ahmad kept a Buy rating; RARE closed at $26.74 and has a consensus price target of $52.60. Jefferies analyst Tycho Peterson kept a Buy rating for DHR, with a $210 target; DHR closed at $192.32 and has a $219.78 consensus target.
Over the past 7 days, alphai's AI scored 1 news story mentioning RARE (Ultragenyx Pharmaceutical Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent RARE coverage spans financial news, earnings and regulation.
In the last 30 days, RARE insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($164K). The most active reporter was Parschauer Karah Herdman, EVP and Chief Legal Officer, with 1 filing. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
Near-term catalyst is FDA decisions on DTX-401 and UX-111, while guidance reaffirmation supports baseline expectations for 2026 cost discipline.
A Priority Review and assigned PDUFA date for an AAV gene therapy create a near-term regulatory catalyst for Ultragenyx.
Street sentiment is bullish for RARE, but the article is primarily a broker-rating recap with no new fundamental datapoint.
Inducement RSU grants are typically non-fundamental, but they confirm new officer hiring and add modest dilution/compensation expense visibility.
This is an insider selling disclosure with no stated operational or financial catalyst; likely limited incremental signal for near-term fundamentals.
alphai scores every news story that mentions RARE with an AI model for sentiment and relevance, and aggregates insider trades from Ultragenyx Pharmaceutical Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Ultragenyx Pharmaceutical (NASDAQ:RARE) reaffirmed revenue and 2026 combined R&D and SG&A guidance, expecting flat to down low single digits from 2025, and at least a 15% decline in 2027. In Q2, Crysvita patient starts rose in Latin America and Turkey, and DOJOLVI had about 675 reimbursed patients in North America. FDA PDUFA dates are Aug. 23 for DTX-401 and Sept. 19 for UX-111.
6 min readThe FDA’s August 2026 Prescription Drug User Fee Act calendar includes target action dates for multiple investigational drugs and therapies. Moderna’s mRNA-1010 has an Aug 5, 2026 PDUFA date. Gilead’s bictegravir/lenacapavir has Aug 27. Lantheus’ MK-6240 has Aug 13. Other listed PDUFA dates cover programs from Capricor, BMS, Jazz, Savara, Ultragenyx, PharmaEssentia, Regeneron, Takeda, and Priovant.
4 min readAnalysts at Bank of America and Jefferies reiterated bullish views on Ultragenyx Pharmaceutical (RARE) and Danaher (DHR). Bank of America analyst Tazeen Ahmad kept a Buy rating; RARE closed at $26.74 and has a consensus price target of $52.60. Jefferies analyst Tycho Peterson kept a Buy rating for DHR, with a $210 target; DHR closed at $192.32 and has a $219.78 consensus target.
2 min readUltragenyx Pharmaceutical (NASDAQ: RARE) said it granted 44,409 restricted stock units to 15 newly hired non-executive officers as an inducement under Nasdaq Listing Rule 5635(c)(4). The compensation committee approved the awards under its Employment Inducement Plan; the grant date was June 16, 2026. RSUs vest over four years, with 25% each anniversary, subject to continued employment.
2 min readHorn Howard (Chief Financial Officer) sold 4,653 shares of Ultragenyx Pharmaceutical Inc. (RARE) at $23.77 ($0.11M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
1 min readKrensavage Asset Management, according to an SEC filing dated May 14, 2026, bought 241,245 shares of Ultragenyx Pharmaceutical (RARE), an estimated $5.43 million based on quarterly average pricing. The fund ended the quarter with 390,879 shares valued at $8.19 million. RARE shares were about $23.94, down roughly 32% over the past year.
4 min readCantor Fitzgerald has increased its price target for Ultragenyx Pharma (NASDAQ: RARE) to $96 from $84, maintaining an Overweight rating. This adjustment follows increased confidence in GTX-102, a treatment for Angelman syndrome, with its probability of success raised to 60%. Despite recent financial misses for Q1 2026, the company reaffirmed its full-year revenue guidance and recently elected three Class I directors.
2 min readThis article details an insider trading activity at Ultragenyx Pharmaceutical Inc. (RARE), specifically a Form 4 filing by director Daniel G. Welch. Welch reported receiving 7,751 shares of common stock as restricted stock units and a stock option for 14,058 shares, with both vesting fully by the company's next Annual Meeting of Stockholders or May 14, 2027. The filing indicates a neutral impact and sentiment regarding these transactions.
2 min readUltragenyx Pharmaceutical Inc.'s CFO, Howard Horn, sold 4,683 shares of common stock at $20.97 per share in an open-market transaction. Following this sale, Horn directly holds 80,351 shares, which include restricted stock units. This transaction was disclosed in a Form 4 filing and is part of a 10b5-1 plan.
2 min readUltragenyx Pharmaceutical announced that the FDA has accepted its Investigational New Drug (IND) application for UX016, an experimental small-molecule prodrug for GNE myopathy (GNEM). A phase I/II clinical trial for UX016 is expected to begin in the latter half of 2026, aiming to assess its safety, efficacy, and pharmacokinetics in adult GNEM patients. The company currently holds a Zacks Rank #3 (Hold) and has four other approved therapies on the market.
3 min read
